You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. A2a AR Agonists for Rheumatoid Arthritis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. AAV-AIBP Therapy for Alzheimer's Disease

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIA

    PROJECT SUMMARY Therapy for Alzheimer’s disease and related dementias (AD/ADRD), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (Aβ) removal from the brain or on targeting genes for which strong associations between their polymorphism and AD/ADRD are established, have had a mixed record of success. We propose a novel strategy to rev ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. A brief iPad-based screening measure for HIV-associated neurocognitive disorders

    SBC: Digital Artefacts LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): HIV-associated neurocognitive disorders (HAND) remain prevalent despite effective anti-retroviral treatments. Cognitive impairments in the current treatment era are often mild and not readily detectable because currentscreening measures (e.g., the HIV Dementia Scale) lack sensitivity to detect subtle impairments in cognitive function. Although more sensitive t ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A Cancer Vaccine for Ovarian and Breast Cancer

    SBC: EPIMMUNE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective of this STTR program is to develop an effective cancer vaccine based on class II T cell epitopes derived from four tumor-associated antigens (TAAs) that are commonly over-expressed in ovary-and breast-derived tumors. The role of CD4+ T cell in eliciting an anti-tumor response is critical. The development of tumor specific CTL and the ge ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Accelerated x-ray therapy planning system PEREGRINE

    SBC: NOMOS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Computerized radiation therapy planning systems (RTP) are essential in Radiation Oncology for quantitative evaluation of radiation doses prior to patient treatment. Among currently available computational methods, the Monte Carlo method of calculating dose distributionsis most universal and accurate. It is believed that Monte Carlo software packages will become ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government